Angelman Syndrome
Conditions
Keywords
Natural History, EEG, ActiMyo, outcome measures, proteomics
Brief summary
The goal of this study is to conduct a prospective, longitudinal assessment of the natural clinical progression of Angelman syndrome (AS) in children and adults. This will be performed by acquiring baseline measurements, and developing effective outcome measures and diagnostic tools for the syndrome, to prepare the healthcare system for forthcoming clinical trials.
Detailed description
This study is being conducted in anticipation of several candidate therapies which are approaching clinical readiness for Angelman syndrome. This study will comprehensively evaluate the natural clinical progression of the disease using scales and questionnaires for the assessment of motor function and global development, motor measuring devices (ActiMyo), and by collecting sleep and seizure diaries. In addition, proteomic analysis and electroencephalography (EEG) recordings will be collected to identify biomarkers which will indicate improvements in disease outcome following treatment.
Interventions
Longitudinal assessment of disease progression of Angelman syndrome in patients
Sponsors
Foundation for Angelman Syndrome Therapeutics UK
Hoffmann-La Roche
University of Oxford
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
For the candidate participants affected by AS: * Genetically confirmed diagnosis of AS * 0-99 years * Male or Female * Obtained consent forms and/or record of consultation by the carers. In this study, the two primary carers for each participant diagnosed with AS will be also considered participants. Carers will have to meet the following inclusion criteria: * Male or Female * \>18 years * Legal carer of the patient diagnosed with AS * Willingness to follow study procedures, as assessed by the research team * Willingness to sign the consent form * Ability to understand all the information regarding the study, as assessed by the research team
Exclusion criteria
* The participant affected by AS may not enter the study if there is any comorbidity (\*) that could potentially affect the results of the study. This will be subject to the clinical judgement of the Chief Investigator (CI) and/or the Principal Investigator (PI). Participants of ongoing (interventional) clinical trials that assess the efficacy of potential treatments will be excluded as assessments need to be done on the basis that represent the natural progression of AS. (\*) This includes any confirmed chronic or acute condition or disease affecting any system(s), which could interfere with the results of the study and/or the compliance with the study procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Scale | 2 years 1 month | Clinical Global Impressions Scale - Angelman Syndrome version (CGI-SAS). Scales whereby practitioner rates from 1 to 7 the overall improvement/deterioration of the participant affected by Angelman Syndrome. One is improved and 7 denotes deterioration. |
| Collection of relevant medical data (retrospective and prospective) | 2 years 1 month | Collection of demographic data, Angelman Syndrome-related medical history, past medical and surgical history, current medication, history of immunisations and family medical history. |
| Neurological assessment scale | 2 years 1 month | Hammersmith Infant Neurological Examination (HINE) (0-2 years ONLY). Maximum global score of 78. Higher scores indicate a higher degree of neurological performance. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gross motor milestones | 2 years 1 month | World Health Organisation (WHO) Motor Milestones. Scale of 6 gross motor milestones. Lower scores denotes worse motor function. |
| Global development assessment scale | 2 years 1 month | Bayley Scales of Infant and Toddler Development - 4 (BSID-4) for Developmental delays. Scale is divided into five domains, which are further divided into subdomains. The first step is to calculate the starting point by beginning with the items that are age appropriate. The starting point is validated if three consecutive items are achieved. If the participant affected by Angelman Syndrome does not achieve three consecutive items in a row at the age-appropriated starting point, the evaluator must go backwards to the lower age-starting point until the participant affected by Angelman Syndrome achieves three items in a row. The assessment stops once five items in a row are not achieved. |
| Aberrant behaviour assessment | 2 years 1 month | Aberrant Behaviour Checklist-Community (ABC-C). This scale comprises 58 items and is divided into five subdomains. The ABC-C is designed on a four-point scale with the lowest score representing less-affected patients while the highest score represents the severest patients. |
| Communication assessment | 2 years 1 month | Observed Reported Communication Assessment (ORCA) Tool. Questionnaire designed to be completed by the patients' main carer and records patient communication. |
| Motor function assessment | 2 years 1 month | Functional Mobility Scale (FMS). Scale which rates the walking ability in three different walking distances, and these distances will be rated on a 6-point scale. |
| Laboratory biomarkers for Angelman syndrome | 2 years 1 month | Proteomic analysis of plasma samples to determine biomarkers of disease progression |
| Electroencephalogram (EEG) activity recordings | 24 hours | Electroencephalogram (EEG) to record brain activity of Angelman Syndrome patients over a 24-hour period (e.g., sleep architecture, number and frequency of seizures, background epileptic activity, delta-rhythmicity) |
| Quality of life assessment for individuals affected by Angelman syndrome | 2 years 1 month | PedsQL-Core Module questionnaires. Questionnaire uses ranking system which depends on the age of patient. |
| Health economics | 2 years and 1 month | Interview with Carer's |
| Clinical trial readiness | 2 years and 1 month | Demographic data collection and facilities preparation |
| Sleep and seizure activity | 2 years 1 month | Sleep and seizure diaries with ready-made questionnaires |
| Quality of Life questionnaires for families of Angelman syndrome patients | 2 years 1 month | PedsQL-Family Module questionnaires. Questionnaire uses ranking system of 1-4 based on frequency. |
| Movement monitoring using wearable device | 2 years 1 month | Continuous movement monitoring using actimetry ActiMyo® in uncontrolled environment (i.e., home) |
Other
| Measure | Time frame | Description |
|---|---|---|
| DNA biobank | 2 years and 1 month | Blood sample collection and DNA extraction and storage |
Countries
United Kingdom
Outcome results
None listed